Treatment of Uraemic Anaemia with Recombinant Human Erythropoietin

  • Claudio Ponticelli
  • Stefano Casati
  • Mariarosaria Campise
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 260)


Several factors have been involved in the pathogenesis of uraemic anaemia: inhibition of erythropoiesis and hyperhaemolysis to uraemic toxins (1); iron deficiency due to blood losses in the extracorporeal circuit (2); severe hyperparathyroidism with osteitis fibrosa (3) ; abnormally high concentrations of aluminium (4). However, there is general agreement that the main cause of uraemic anaemia is the insufficient production of erythropoietin from the diseased kidneys (5).


Haemodialysis Patient Atrial Natriuretic Peptide Recombinant Human Erythropoietin Extracorporeal Circuit Recombinant Erythropoietin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Markson, J.L., Renniec, J.B.: The anaemia of chronic renal insufficiency. Scott. Med. J. 1:320 (1970)Google Scholar
  2. 2.
    Loge, J.P., Lange, R.D., Moore, C.V.: Characterization of the anemia associated with chronic renal insufficiency. Am. J. Med. 24:4 (1958).PubMedCrossRefGoogle Scholar
  3. 3.
    Weinberg, S.G., Lubin, A., Wiener, S., Deoras, M.P., Ghose, M.K., Kogelmann, R.C.: Myelofibrosis and renal osteodystrophy. Am. J. Med. 63: 755 (1977).PubMedCrossRefGoogle Scholar
  4. 4.
    Kaiser, L., Schwartz, K.A.: Aluminium induced anaemia. Am. J. Kidney Dis. 6:348 (1985) .PubMedGoogle Scholar
  5. 5.
    Eschbach, J.W., Adamson, J.W.: Anaemia of end stage renal disease. Kidney Int. 28:1 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W.: Correction of anaemia of end stage renal disease with recombinant human erythropoietin. N. Enal. J. Med. 316:73 (1987).CrossRefGoogle Scholar
  7. 7.
    Winearls, C.G., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R., Cotes, P.M.: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2:1175 (1986).PubMedCrossRefGoogle Scholar
  8. 8.
    Casati, S., Passerini, P., Campise, M., Graziani, G., Cesana, B., Perisic, M. , Ponticelli, C.: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Brit. Med. J. 4:1017 (1987) .CrossRefGoogle Scholar
  9. 9.
    Sundal, E., Bariety, J., Blumberg, A., Bommer, J., Canaud, B., Danielson, B., Kreis, H., Lamperi, S., Michielsen, P., Rhyner, K. , Ponticelli, C., Schaefer, R.M. , Verbeelen, D. , Zehnder, C., Kaeser, U. : Correction of the anaemia of chronic renal failure with recombinant human erythropoietin: results from a multicentre study in 150 haemotransfusion dependent patients (submitted for publication).Google Scholar
  10. 10.
    Eschbach, J.W., Adamson, J.W.: Correction of the anemia of hemodialysis patients with recombinant human erythropoietin. Results of a multicentre study. Kidney Int. 33:189 (1988).Google Scholar
  11. 11.
    Bommer, J., Kugel, M., Schoeppe, W., Brunkhorst, R., Samtleben, W., Bramsiepe, W., Scigalla, P.: Dose related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicentre trial in patients with end-stage renal disease. Contr. Nephrol. Vol. 66, p 85, Karger, Basel, (1988).Google Scholar
  12. 12.
    Akizawa, T., Koshikawa, S., Takaku, F., Urabe, A., Akiyama, N., Mimura, N., Otsubo, O., Nihei, H., Suzuki, Y., Kawaguchi, Y., Ota, K., Kubo, K., Marumo, F., Maeda, T.: Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multi institutional study in Japan. Int. J. Artif. Organs. 11; 343 (1988).PubMedGoogle Scholar
  13. 13.
    Eschbach, J.W., Adamson, J.W.: Recombinant human erythropoietin: Implications for nephrology. Am. J. Kidney Dis. 11:203 (1988).PubMedGoogle Scholar
  14. 14.
    Hampl, H., Riedel, E., Wendel, G., Stabeil U., Kessel, M.: Influence of parathyroid hormone on exogenous erythropoietin stimulated erythropoiesis in hemodialysis patients. Kidney Int. 33:224 (1988).Google Scholar
  15. 15.
    Winearls, C.G.: Use of erythropoietin in patients with end-stage renal disease. Royal Soc. Med. 1:2 (1988).Google Scholar
  16. 16.
    Bommer, J., Alexiou, C., Müller-Bühl, U. , Eifert, J., Ritz, E.: Recombinant human erythropoietin therapy in hemodialysis patients. Dose determination and clinical experience. Nephrol. Dial. Transpl. 2:23 (1987).Google Scholar
  17. 17.
    Mayer, G., Thum, J. Cada, E.M., Stummvoll, H.K., Graf, H.: Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int. 34:525 (1988).PubMedCrossRefGoogle Scholar
  18. 18.
    Grützmacher, P., Bergmann M., Löw, I., Schoeppe, W.: Cardiac changes in haemodialysis patients treated by recombinant human erythropoietin. Int. Soc. Blood Purification, Vicenza June, Abstr. 36 (1988).Google Scholar
  19. 19.
    London, G.M. , Zins, B. , Naret, C., Pannier, B., Berthelot, J.M., Peteriongo, F., Drueke, T., Jacquot, C.: Hemodynamic changes in haemodialysis patients in response to recombinant erythropoietin. EDTA-ERA Madrid, Abstr. 211 (1988).Google Scholar
  20. 20.
    Kühn, K., Talartschik, H., Koch, K.M., Eisenhauer, T., Nonnast-Daniel, B., Scheler, F., Brunkhorst, R., Reimers, E.: Plasma atrial natriuretic peptide levels after partial correction of renal anemia by recombinant human erythropoietin. EDTA-ERA Madrid, Abstr. 210 (1988).Google Scholar
  21. 21.
    Mangiarotti, R., Pierini, A., Casati, S., Passerini, P., Ambroso, G.C., Pini, C., Graziani, G. : Modificazioni delia funzionalità cardiaca nell’emodializzato in trattamento con eritropoietina. Nefroloqia, Acta Medica, Roma 419 (1987).Google Scholar
  22. 22.
    Paganini, E., Thomas, T., Fouad, F., Garcia, J., Bravo, E.: The correction of anemia in hemodialysis patients using recombinant human erythropoietin: hemodynamic effects. Kidney Int. 33:204 (1988).Google Scholar
  23. 23.
    Deykin, D.: Uremic bleeding. Kidney Int. 24:698 (1983).PubMedCrossRefGoogle Scholar
  24. 24.
    Livio, M., Marchesi, D., Remuzzi, G., Gotti, E., Mecca, G., DeGaetano, G.: Uraemic bleeding: role of anemia and beneficial effect of red-cell transfusions. Lancet 2:1013 (1982).PubMedCrossRefGoogle Scholar
  25. 25.
    Moia, M., Vizzotto, L., Cattaneo, M., Mannucci, P.M., Casati, S., Ponticelli, C.: Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 2:1227 (1987).PubMedCrossRefGoogle Scholar
  26. 26.
    Ishibashi, T., Koziol, J.A., Burstein, S.A.: Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J. Clin. Invest. 79: 286 (1987).PubMedCrossRefGoogle Scholar
  27. 27.
    Grützmacher, P., Bergmann, M., Nattermann, U., Weinreich, T., Reimers, E., Pollak, M.: Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. Contr. Nephrol. Vol. 66, p 104, Karger, Basel, (1988).Google Scholar
  28. 28.
    Jacquot, C., Ferragu-Haguet, M. , Lefebvre, A., Berthelot, J.M., Peteriongo, F., Castaigne, J.P.: Recombinant human erythropoietin and blood pressure. Lancet 2:1083 (1987).PubMedCrossRefGoogle Scholar
  29. 29.
    Tomson, C.R.V., Venning, M.C., Ward, M.K.: Blood pressure and erythropoietin. Lancet 1:351 (1988).CrossRefGoogle Scholar
  30. 30.
    Edmunds, M.S., Walls, J.: Blood pressure and erythropoietin. Lancet 1:352 (1988).Google Scholar
  31. 31.
    Neff, M.S., Kim, K.E., Persoff, M., Onesti, G., Swartz, C.: Haemodynamics of uraemic anaemia. Circulation 43:876 (1971).PubMedGoogle Scholar
  32. 32.
    Capelli, J.P., Kasparian, H.: Cardiac work demands and left ventricular function in end-stage renal disease. Ann. Intern. Med. 86:261 (1977).PubMedGoogle Scholar
  33. 33.
    Colemann, T.G.: Hemodynamics of uremic anemia. Circulation 45:510 (1972).Google Scholar
  34. 34.
    Martin, J., Moncada, S.: Blood pressure, erythropoietin and nitric oxide. Lancet 1:644 (1988).PubMedCrossRefGoogle Scholar
  35. 35.
    Schaefer, R.M., Kuerner, B., Zech, M., Denninger, G., Borneff, C., Heidland, A.: Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. Int. J. Artif. Organs 11:249 (1988).PubMedGoogle Scholar
  36. 36.
    Stivelmann, J., van Wick, D., Kirlin, D., Ogden, D.: Use of recombinant erythropoietin with high flux dialysis does not worsen azotemia or shorten access survival. Kidney Int. 33:239 (1988).Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Claudio Ponticelli
    • 1
  • Stefano Casati
    • 1
  • Mariarosaria Campise
    • 1
  1. 1.Divisione di NefrologiaIRCCS Ospedale MaggioreMilanItaly

Personalised recommendations